Clinical Applications of Targeted Alpha Particle Therapies

Aug
14
2014
03:00 PM - 04:00 PM
David A. Scheinberg, Sloan Kettering Institute, New York, NY
Physics Division Seminar
Building 4500N, Weinberg Auditorium, Room I-126
CONTACT :
Email: Alfredo Galindo-Uribarri
Phone:865.574.6124
SHARE
    
 

Alpha particles are among the most potent cytotoxic agents known. Efforts to selectively deliver them to cancer cells have been underway for nearly 2 decades. Monoclonal antibodies are highly selective and safe vehicles that can be designed to target tumor-specific cell surface or intracellular antigens and carry either alpha particle emitting metals or nano-scale generators of radioisotopes. Upon binding, the complexes can be internalized into the cells. Monoclonal antibody-targeted alpha particles offer extraordinary potency and selectivity, and are safe and effective in various models of human cancers. They have demonstrated anti-tumor activity in humans. The short-lived emitters are well-tolerated in patients. Monoclonal antibody-targeted nano-generators of alpha-emitting isotopes have been shown to be effective in models of disseminated cancers (leukemia and lymphoma) and solid tumors (prostate, colon, ovary, neuroblastoma) as well as against normal neo-vasculature of tumors. They can be administered systemically, locally, regionally, and intrathecally. Nanomaterial based carriers provide an increase in delivered load as well. The targeted alpha generators are active in early human clinical trials and have potential for commercial development since they offer great improvements in potency, cost and feasibility. Phase 2 trials of both alpha approaches are in progress.

Refreshments served at 2:40 PM.

ASK ORNL

We're always happy to get feedback from our users. Please use the Comments form to send us your comments, questions, and observations.